Lawmaker Urges FDA Not To Allow Off-Label Loophole

Law360, New York (November 30, 2007, 12:00 AM EST) -- The chair of the U.S. House of Representatives Oversight Committee sent a letter to the U.S. Food and Drug Administration Friday, urging the agency to rethink a recent internal draft guidance that would allow drug companies to promote drugs and devices for off-label use without FDA approval.

In his letter to FDA Commissioner Andrew C. von Eschenbach, Rep. Henry Waxman (D-Calif.) called the agency’s October draft guidance “ill-advised” and claimed it would “carve a large loophole in the law” by allowing drug and device manufacturers to...
To view the full article, register now.